M. Laird Forrest

University of Kansas — United States

Materials Science · Physical Sciences

42h-index8.2kcitations146works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nanoparticle-Based Drug Delivery(25), RNA Interference and Gene Delivery(21), Nanoplatforms for cancer theranostics(19), Cancer Treatment and Pharmacology(13), Immunotherapy and Immune Responses(12)

Publications144 total

Development of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes
Journal of Drug Delivery Science and Technology·2025Open Access
Development of Long-acting Formulation for Hydrophobic Kifunensine Analogues as Potent Inhibitors of Type I Mannosidase Enzymes (Dataset)
2025
An In Vivo Study on the Feasibility of Catheter-Assisted Pulsed Focused Ultrasound Ablation of Atherosclerotic Plaques
Ultrasound in Medicine & Biology·2025Open Access
Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy
Drug Delivery and Translational Research·2025· 3 cited
Magnetic Immunoprecipitation Assay for the Isolation of Adalimumab and Degradation Products in Preclinical Biological Samples
SSRN Electronic Journal·2025Open Access
Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
Molecular Pharmaceutics·2024· 6 cited
An <i>ex vivo</i> investigation on the potential of catheter-assisted pulsed focused ultrasound ablation for arterial plaques
The Journal of the Acoustical Society of America·2024
Pulsed focused ultrasound ablation assisted by a surface modified catheter for thrombolysis: a feasibility study
Frontiers in Acoustics·2024· 1 citedOpen Access
Investigating the potential of catheter‐assisted pulsed focused ultrasound ablation for atherosclerotic plaques
Medical Physics·2024· 5 citedOpen Access
Pharmacokinetic Behaviors of Orally Administered Drugs
2023
Supplementary Information from Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition
2023Open Access
Supplementary Information from Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition
2023Open Access
Data from Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition
2023Open Access
Data from Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition
2023Open Access
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors
Translational Medicine Communications·2023· 1 citedOpen Access
Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors
Molecular Pharmaceutics·2023· 8 cited
Rational Drug Design of Targeted and Enzyme-Cleavable Vitamin E Analogs as a Neoadjuvant to Chemotherapy: <i>In Vitro</i> and <i>In Vivo</i> Evaluation on Reduction of the Cardiotoxicity Side Effect of Doxorubicin
ACS Pharmacology & Translational Science·2023· 6 citedOpen Access
Glatiramer Acetate Complexed with CpG as Intratumoral Immunotherapy in Combination with Anti-PD-1
Molecular Pharmaceutics·2022· 11 cited
Conformational Changes and Drivers of Monoclonal Antibody Liquid-Liquid Phase Separation
Journal of Pharmaceutical Sciences·2022· 8 citedOpen Access
Hyaluronic acid carrier-based photodynamic therapy for head and neck squamous cell carcinoma
Photodiagnosis and Photodynamic Therapy·2021· 9 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Neal M. Davies(15), Shuang Cai(11), Glen S. Kwon(11), Jaime A. Yáñez(9), Cory Berkland(7), Yumei Xie(6), Mark S. Cohen(6), Connie M. Remsberg(5), Shaofeng Duan(5), Daniel W. Pack(4), Taryn R. Bagby(4), Sharadvi Thati(4), May P. Xiong(4), Ti Zhang(4), Casey L. Sayre(3), Yusuke Ohgami(3), Kristin Aillon(2), Satish K. Nune(2), Padmaja Gunda(2), Praveen K. Thallapally(2)